MX2021002967A - Metodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores ccr3. - Google Patents
Metodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores ccr3.Info
- Publication number
- MX2021002967A MX2021002967A MX2021002967A MX2021002967A MX2021002967A MX 2021002967 A MX2021002967 A MX 2021002967A MX 2021002967 A MX2021002967 A MX 2021002967A MX 2021002967 A MX2021002967 A MX 2021002967A MX 2021002967 A MX2021002967 A MX 2021002967A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- disease
- ccr3
- inhibitors
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862737017P | 2018-09-26 | 2018-09-26 | |
| PCT/US2019/052995 WO2020069008A1 (fr) | 2018-09-26 | 2019-09-25 | Procédés et compositions pour traiter des troubles liés au vieillissement au moyen d'inhibiteurs de ccr3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021002967A true MX2021002967A (es) | 2021-08-11 |
Family
ID=69953286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021002967A MX2021002967A (es) | 2018-09-26 | 2019-09-25 | Metodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores ccr3. |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP3856195A4 (fr) |
| JP (1) | JP7528065B2 (fr) |
| KR (1) | KR20210065950A (fr) |
| CN (1) | CN112789044A (fr) |
| AU (1) | AU2019346456A1 (fr) |
| BR (1) | BR112021004938A2 (fr) |
| CA (1) | CA3111433A1 (fr) |
| CL (1) | CL2021000724A1 (fr) |
| CO (1) | CO2021003713A2 (fr) |
| EA (1) | EA202190463A1 (fr) |
| IL (1) | IL281578A (fr) |
| MA (1) | MA53743A (fr) |
| MX (1) | MX2021002967A (fr) |
| SG (1) | SG11202102105VA (fr) |
| TW (1) | TW202027752A (fr) |
| WO (1) | WO2020069008A1 (fr) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200538098A (en) * | 2004-03-22 | 2005-12-01 | Astrazeneca Ab | Therapeutic agents |
| EP1996551A2 (fr) * | 2006-03-07 | 2008-12-03 | AstraZeneca AB | Derives de piperidine, leur procede de preparation, leur utilisation comme agents therapeutiques et compositions pharmaceutiques les contenant |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| PE20150925A1 (es) | 2009-04-22 | 2015-06-14 | Axikin Pharmaceuticals Inc | Antagonistas de ccr3 de arilsulfonamida 2,5-disustituida |
| US20160208011A1 (en) * | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| UA109290C2 (uk) * | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| CN110650740A (zh) * | 2017-04-05 | 2020-01-03 | 万能溶剂有限公司 | 使用ccr3抑制剂治疗视网膜相关疾病的方法和组合物 |
| BR112019020798A2 (pt) * | 2017-04-05 | 2020-04-28 | Alkahest Inc | métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3 |
-
2019
- 2019-09-25 MX MX2021002967A patent/MX2021002967A/es unknown
- 2019-09-25 SG SG11202102105VA patent/SG11202102105VA/en unknown
- 2019-09-25 WO PCT/US2019/052995 patent/WO2020069008A1/fr active Application Filing
- 2019-09-25 CN CN201980063258.7A patent/CN112789044A/zh active Pending
- 2019-09-25 KR KR1020217008493A patent/KR20210065950A/ko unknown
- 2019-09-25 EP EP19867321.2A patent/EP3856195A4/fr active Pending
- 2019-09-25 AU AU2019346456A patent/AU2019346456A1/en not_active Abandoned
- 2019-09-25 EA EA202190463A patent/EA202190463A1/ru unknown
- 2019-09-25 BR BR112021004938-0A patent/BR112021004938A2/pt not_active Application Discontinuation
- 2019-09-25 CA CA3111433A patent/CA3111433A1/fr active Pending
- 2019-09-25 JP JP2021517342A patent/JP7528065B2/ja active Active
- 2019-09-25 MA MA053743A patent/MA53743A/fr unknown
- 2019-09-26 TW TW108134938A patent/TW202027752A/zh unknown
-
2021
- 2021-03-17 IL IL281578A patent/IL281578A/en unknown
- 2021-03-23 CL CL2021000724A patent/CL2021000724A1/es unknown
- 2021-03-24 CO CONC2021/0003713A patent/CO2021003713A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210065950A (ko) | 2021-06-04 |
| CA3111433A1 (fr) | 2020-04-02 |
| JP7528065B2 (ja) | 2024-08-05 |
| JP2022502441A (ja) | 2022-01-11 |
| BR112021004938A2 (pt) | 2021-06-01 |
| CL2021000724A1 (es) | 2021-10-15 |
| MA53743A (fr) | 2022-01-05 |
| IL281578A (en) | 2021-05-31 |
| TW202027752A (zh) | 2020-08-01 |
| EA202190463A1 (ru) | 2021-06-29 |
| WO2020069008A1 (fr) | 2020-04-02 |
| EP3856195A1 (fr) | 2021-08-04 |
| SG11202102105VA (en) | 2021-04-29 |
| EP3856195A4 (fr) | 2022-06-22 |
| CN112789044A (zh) | 2021-05-11 |
| AU2019346456A1 (en) | 2021-04-15 |
| CO2021003713A2 (es) | 2021-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019011988A (es) | Metodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores de ccr3. | |
| WO2018015573A3 (fr) | Modulateurs du clivage de trem2 et leurs utilisations | |
| MX2018011453A (es) | Moduladores alostericos de receptores de acetilcolina nicotinicos. | |
| GEP201706608B (en) | 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases | |
| EA201991755A1 (ru) | Бициклические бисгетероарильные производные в качестве модуляторов агрегации белков | |
| MX2023012694A (es) | 2-arilbenzimidazoles como activadores de ppargc1a para tratar enfermedades neurodegenerativas. | |
| EA201991375A1 (ru) | Бицикло[1.1.1]пентановые ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| CL2020000070A1 (es) | Agentes, usos y métodos para el tratamiento. | |
| EA200971050A1 (ru) | Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений | |
| TW201613890A (en) | Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators | |
| TW200635589A (en) | Therapeutic agents | |
| PH12020551779A1 (en) | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | |
| WO2018013775A3 (fr) | Compositions de granulines et utilisations associées | |
| MX2020013115A (es) | Compuestos de tetrahidrobenzofuro[2,3-c]piridina y beta-carbolina para el tratamiento, el alivio o la prevencion de trastornos asociados con los agregados de tau. | |
| JP2017519798A5 (fr) | ||
| MX2021002967A (es) | Metodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores ccr3. | |
| WO2020117031A3 (fr) | Composition et méthode d'inhibition de l'accumulation et/ou de l'agrégation de bêta-amyloïdes | |
| WO2020092102A3 (fr) | Modulateurs allostériques 3-(1h-pyrazol-4-yl)pyridine du récepteur muscarinique m4 de l'acétylcholine | |
| EA201991753A1 (ru) | Алкоксибисгетероарильные производные в качестве модуляторов агрегации белков | |
| EA201992188A1 (ru) | Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов | |
| MX2021007551A (es) | Acidos biliares 2-fluorados para el tratamiento de enfermedades neurodegenerativas. | |
| EP4069315A4 (fr) | Stabilisation de rétromère permettant le traitement de la maladie d'alzheimer et d'autres troubles neurodégénératifs | |
| MX2022007654A (es) | Compuestos inhibidores de la oga. | |
| MA54630B1 (fr) | N,n-bis-2-mercaptoéthyle isophtalamide pour le traitement des maladies neurodégénératives | |
| MX2017012239A (es) | Metodos y composiciones para la administracion intravenosa de fumaratos para el tratamiento de enfermedades neurologicas. |